{"id":19214,"date":"2024-10-21T08:30:27","date_gmt":"2024-10-21T08:30:27","guid":{"rendered":"https:\/\/interhospi.com\/?p=19214"},"modified":"2024-10-17T12:59:08","modified_gmt":"2024-10-17T12:59:08","slug":"atricures-encompass-clamp-receives-ce-mark-approval","status":"publish","type":"post","link":"https:\/\/interhospi.com\/atricures-encompass-clamp-receives-ce-mark-approval\/","title":{"rendered":"AtriCure\u2019s EnCompass Clamp receives CE mark approval"},"content":{"rendered":"
\n

<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

AtriCure\u2019s EnCompass Clamp receives CE mark approval<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

AtriCure has announced regulatory approval for the sale of its EnCompass\u00ae Clamp in CE-marked countries within the European Union. This development follows the device\u2019s FDA 510(K) clearance and subsequent launch in the United States in 2022.<\/p>\n

<\/p>\n

\"Atricure<\/h3>\n

Device features and functionality<\/strong><\/h3>\n

The EnCompass Clamp is designed to simplify and expedite cardiac ablation procedures in open-chest surgeries. It facilitates comprehensive epicardial ablation of the left atrium, potentially reducing procedure time to a matter of minutes. The device incorporates features from AtriCure\u2019s existing Synergy\u2122 Clamp family, including parallel closure, uniform pressure, and customised power delivery using Synergy radiofrequency (RF) technology.<\/p>\n

A notable innovation in the EnCompass Clamp is its magnetic guide system, which allows for more efficient placement with minimal tissue dissection. The clamp\u2019s design accommodates various cardiac anatomies, supporting surgical ablation in procedures where the atrium would typically remain closed, such as coronary artery bypass grafting (CABG) and aortic valve replacement (AVR).<\/p>\n

Clinical implications<\/strong><\/h3>\n

AtriCure estimates that approximately 400,000 cardiac surgeries are performed annually in the European Union, suggesting a significant potential market for the EnCompass Clamp.<\/p>\n

Michael Carrel, President and CEO of AtriCure, commented: \u201cWe have seen this product have a positive impact in the United States over the last two years by advancing treatment concomitant to cardiac surgery. We are excited to offer this safe, innovative, and effective therapy to patients and our physician partners in Europe.\u201d<\/p>\n